

I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.

Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.

The Health Board have 12 patients registered on the data base; all have mild haemophilia.

Patients with moderate or severe haemophilia are managed in University Hospital of Wales (UHW).

Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF
- Any other products

None.

Q3. For patients treated with Advate in the last three months, please provide:

- the number of haemophilia A patients treated prophylactically
- the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)

None.

Q4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)

- **Hemlibra (standalone)**
- **Hemlibra in combination with any Factor VIII**
- **NovoEight**
- **NovoSeven RT**
- **Obizur**
- **Refacto AF**
- **Any other products**

None.